There is a vast array of antibody variants, including multispecific (msAb), bispecific antibodies (bsAb), antibody fragments (Fab, dAb, scFv), and antibody-drug conjugates (ADC). But with this diversity comes challenges. Developing purification processes for antibody variants is not always straightforward and the platform approaches conveniently used for many traditional mAbs cannot be used.
Learn more about developing purification protocols for the diversified therapeutic antibody pipelines.
